|
| | HR0129 | | LRB104 12087 MST 22185 r |
|
|
1 | | HOUSE RESOLUTION |
2 | | WHEREAS, Vaccination is proven to be a safe, invaluable |
3 | | tool to proactively safeguard public health and prevent the |
4 | | devastating effects of vaccine-preventable diseases; and |
5 | | WHEREAS, Vaccination has averted over 154 million deaths |
6 | | globally since 1974, of which 146 million were among children |
7 | | younger than five years of age; and |
8 | | WHEREAS, Vaccination has greatly reduced morbidity and |
9 | | mortality by eradicating vaccine-preventable diseases (e.g., |
10 | | smallpox) and has greatly reduced the incidence of infections |
11 | | such as meningitis, measles, polio, and rubella; and |
12 | | WHEREAS, Timely meningococcal vaccination in children and |
13 | | young adults helps protect against the debilitating effects of |
14 | | meningococcal disease, including death, and has led to a |
15 | | significant decrease in incidence; and |
16 | | WHEREAS, Vaccination for highly contagious diseases such |
17 | | as measles is incredibly important; in order to achieve herd |
18 | | immunity against measles, 95% of the population must be |
19 | | vaccinated; if measles vaccination coverage rates drop below |
20 | | that threshold, outbreaks and preventable deaths will |
21 | | ultimately occur; therefore, maintaining high vaccine coverage |
|
| | HR0129 | - 2 - | LRB104 12087 MST 22185 r |
|
|
1 | | rates is critical to protect the public and prevent |
2 | | transmission; and |
3 | | WHEREAS, An analysis of costs associated with invasive |
4 | | meningococcal disease outbreaks found that the average cost |
5 | | per outbreak containment strategy was almost $440,000 |
6 | | ($299,641 and $579,851 for small and large containment |
7 | | strategies, respectively); and |
8 | | WHEREAS, Among the approximately 117 million children born |
9 | | during 1994-2023 in the United States, vaccination averted 508 |
10 | | million lifetime cases of illness, 32 million |
11 | | hospitalizations, and 1.1 million deaths, resulting in |
12 | | estimated savings of $540 billion in direct medical costs and |
13 | | $2.7 trillion in societal costs; and |
14 | | WHEREAS, Vaccination can prevent the development of |
15 | | cancers later in life (e.g., human papillomavirus vaccination, |
16 | | which has contributed to a 65% reduction in cervical cancer |
17 | | incidence over the last decade); and |
18 | | WHEREAS, Vaccination for four common diseases in older |
19 | | adults, including shingles, is estimated to prevent 64 million |
20 | | cases and $185 billion in treatment costs over the next 30 |
21 | | years in the United States; and |
|
| | HR0129 | - 3 - | LRB104 12087 MST 22185 r |
|
|
1 | | WHEREAS, While vaccinating children provides substantial |
2 | | health and economic benefit, vaccinating adults is also |
3 | | important; many childhood vaccines provide life-long |
4 | | protection; however, immunity can decrease over a person's |
5 | | lifetime, and some vaccine-preventable diseases can be more |
6 | | severe in adults; and |
7 | | WHEREAS, There continues to be disease burden in adults, |
8 | | especially in those with comorbidities, advanced age, or |
9 | | immunocompromising conditions, warranting continued, timely |
10 | | vaccination, especially against viruses that change frequently |
11 | | (e.g., influenza, COVID-19); and |
12 | | WHEREAS, For example, vaccination against shingles for |
13 | | high-risk adults aged 19 and older, as well as all adults aged |
14 | | 50 and older, has proven highly effective in preventing both |
15 | | the infection and its transmission, offering long-lasting |
16 | | protection for several years after immunization; and |
17 | | WHEREAS, For example, respiratory syncytial virus |
18 | | vaccination in older adults is an effective preventive measure |
19 | | that reduces the likelihood of hospitalization and critical |
20 | | illness due to respiratory syncytial virus infection; and |
21 | | WHEREAS, Vaccines remain a safe and effective public |
22 | | health measure; in the United States, vaccines undergo a |
|
| | HR0129 | - 4 - | LRB104 12087 MST 22185 r |
|
|
1 | | thorough regulatory review process, which includes Food and |
2 | | Drug Administration (FDA) approval and a recommendation from |
3 | | the Advisory Committee on Immunization Practices (ACIP) after |
4 | | careful evaluation; therefore, be it |
5 | | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE |
6 | | HUNDRED FOURTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that |
7 | | we declare April 10, 2025 as Vaccine Awareness Day in the State |
8 | | of Illinois to educate the public about the importance of |
9 | | vaccinations, initiate meaningful dialogue around |
10 | | vaccinations, and encourage the uptake of vaccines; and be it |
11 | | further |
12 | | RESOLVED, That we urge the Illinois Department of Health |
13 | | to continue to promote to healthcare providers and the people |
14 | | of this state that vaccinations are a highly effective and |
15 | | safe public health measure and increase public awareness about |
16 | | the importance of all Illinois residents receiving recommended |
17 | | immunizations, and to promote outreach and education efforts |
18 | | concerning vaccinations; and be it further |
19 | | RESOLVED, That we urge the Illinois Department of Health |
20 | | to continue to prioritize immunization initiatives, develop |
21 | | policies, and invest in immunization infrastructure to ensure |
22 | | broad and open access to immunizations to safeguard public |
23 | | health and protect the well-being of Illinois residents. |